Tranche 1 Warrants (emergence), 96.4M unexercised at 30 June 2026

Jan 23, 2024 · Closed

Edit

Terms of issuance

Instrument

Warrants / purchase right

Principal

missing — add on communication

Net proceeds

missing — add on communication

Coupon

missing — add on communication

Issue date

Jan 23, 2024

Maturity

missing — add on communication

Seniority

missing — add on communication

Conversion ratio

missing — add on communication

Settlement

physical

Conversion terms

Reference stock price

missing — add on communication

Conversion premium

n/acalculated from conversion price & reference stock price

Conversion price

missing — add on communication

Underlying shares

96,361,000calculated: principal ÷ conversion price, unless directly stated

Dilution %

n/acalculated: underlying shares ÷ basic shares outstanding as of issue date

Conversion window opens

missing — add on communication

Early conversion trigger

missing — add on communication

Early conversion threshold

n/acalculated: conversion price × trigger %

Economic analysis

Effective annual cost

n/acalculated: coupon + capped-call cost amortized over the note's life — needs coupon, maturity, and (if hedged) capped-call cost

Interest savings vs. plain debt

n/anot shown — would require an assumed comparable straight-debt rate, which we do not fabricate

Implied option value / volatility

n/anot shown — would require an assumed volatility input, which we do not fabricate

Breakeven

n/anot shown — would require assumed reinvestment/discount-rate assumptions, which we do not fabricate

Context

Shares outstanding (as of issue date)

n/ano datapoint on or before the issue date

Stock price / market cap (as of issue date)

n/ano price on or before the issue date

Use of proceeds

Chapter 11 emergence warrants (Tranche 1), outstanding at 30 June 2026

Other financing outstanding (excl. this instrument)

3.00% Convertible Senior Notes due 2029 ($460.0M), 0.00% Convertible Senior Notes due 2031 ($625.0M), Senior secured term loan facility ($1.00B), 7.750% Senior Secured Notes due 2031 (Core Scientific Finance I LLC) ($3.30B), AMD warrant, up to 30M shares at $23.47 (12,222 shares per MW leased; ~6.5M vested on 377 MW), Letter of credit facility ($500.0M), Senior secured revolving credit facility ($100.0M)

— of which existing debt

$5.99B

Existing cash

n/anot tracked in the system yet

Anti-dilution adjustment terms

missing — add on communication

Related acquisition

none

Related deal

none

Related site

none

Sources

ClosedCore Scientific reports second quarter 2026 results

Jan 23, 2024